Predictive factors for relapse of @entity302 after @entity4545 therapy in XXXX .

@entity1 @entity4545 @entity410 @entity739 @entity302
PURPOSE: To investigate whether serial electroencephalographic (EEG) findings can predict relapse of @entity302 after synthetic @entity4545 (ACTH) therapy in @entity1 with @entity739 ( @entity739 ). SUBJECTS AND METHODS: Thirty-nine @entity739 @entity1 (8 cryptogenic and 31 symptomatic) were included in this study. These @entity1 received ACTH therapy for the first time and were regularly followed up for more than three years at our hospital. Sixteen @entity1 (41.0%) showed @entity410 relapse (relapse group) and 23 @entity1 (59.0%) did not show relapse (non-relapse group). We used survival analysis to investigate the influence of etiology and presence of @entity302 discharges after the ACTH therapy on @entity410 outcome. RESULTS: Immediately after the ACTH therapy, etiology was associated with @entity410 outcome (p=0.003). In the early stage (1 month after the ACTH therapy), only the presence of @entity302 discharges (p=0.001) had a significant association with @entity410 outcome, regardless of etiology. Because all relapsed @entity1 were in the symptomatic group, we performed the same statistical analysis on symptomatic @entity739 @entity1 data only. We found that the group with no @entity302 discharges on EEG showed a significantly higher @entity410 -free rate than those with @entity302 discharges in the early stage (p=0.0091). CONCLUSION: This study demonstrated that serial EEG findings after ACTH therapy are significantly related to relapse of @entity302 .
